In 2018, the FDA said it was recalling valsartan medications because of their contamination with cancer-causing substances. Teva voluntarily recalled its valsartan drugs in 2018 for products distributed as early as October 2015.
In its lawsuit, filed Aug. 7 in the U.S. District Court for the District of New Jersey, Humana aims to recover “substantial” costs the insurer said it incurred from recalling and replacing Teva’s generic blood pressure medication for members. Humana said the valsartan-containing drugs had high levels of N-nitrosodimethylamine, or NDMA, a cancer-causing chemical when ingested at high levels.
Becker’s reached out to Teva for comment on the lawsuit. This article will be updated as more information becomes available.
More articles on payers:
Fraudulent coding led CMS to overpay Cigna $1.4B, Justice Department says
5 payers that made $1B+ in Q2
Which states haven’t expanded Medicaid?
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.